Coronary collaterals improve prognosis in patients with ischemic heart disease

Jakub J Regieli1, J Wouter Jukema, Hendrik M Nathoe

  • 1Department of Cardiology, University Medical Center Utrecht, The Netherlands.

Insights

Coronary collaterals improve cardiovascular outcomes in patients with ischemic heart disease. This protective effect is significant and independent of the extent of coronary artery disease burden.

Area of Science:

  • Cardiology
  • Vascular Biology
  • Clinical Prognosis

Background:

  • Coronary collateral vessels are an adaptive response to ischemic heart disease (IHD).
  • Their protective role in obstructive coronary artery disease, especially in extensive disease, remains debated.
  • This study investigates the prognostic value of coronary collateral circulation in cardiovascular outcomes.

Purpose of the Study:

  • To evaluate the impact of coronary collateral circulation on cardiovascular outcomes.
  • To determine the clinical prognostic value of collaterals.
  • To assess if the protective effect of collaterals is influenced by the burden of IHD.

Main Methods:

  • Analysis of data from the REGRESS study (879 male participants).
  • Assessment of spontaneously visible coronary collaterals on angiography.
  • Follow-up for 24 months, recording myocardial infarction, cardiac death, and revascularization procedures.
  • Proportional hazard analysis adjusted for confounders and IHD burden factors.

Main Results:

  • Event-free survival at two years was significantly higher in patients with collaterals (92%) compared to those without (84%).
  • Coronary collaterals reduced the risk of adverse cardiovascular events (adjusted Hazard Ratio 0.38).
  • The protective effect of collaterals was consistent across different extents of IHD burden (interaction p=0.99).

Conclusions:

  • Angiographically assessed coronary collaterals are a significant clinical predictor of cardiovascular prognosis.
  • Coronary collaterals offer a protective effect on outcomes in a wide range of patients.
  • This protective benefit is independent of the overall disease burden, even in extensive IHD.
Abstract

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...